PL3313401T3 - Nanocząsteczki zawierające sirolimus i albuminę do stosowania w leczeniu nowotworów z komórek epitelioidnych - Google Patents

Nanocząsteczki zawierające sirolimus i albuminę do stosowania w leczeniu nowotworów z komórek epitelioidnych

Info

Publication number: PL3313401T3
Authority: PL; Poland
Prior art keywords: sirolimus; nanoparticles; albumin; cell tumors; epithelioid cell
Prior art date: 2015-06-29

Application number

PL16818717T

Other languages

English (en)

Inventor

Neil P. Desai

Original Assignee

Abraxis Bioscience, Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-29

Filing date

2016-06-29

Publication date

2022-02-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57609139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3313401(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-06-29 Application filed by Abraxis Bioscience, Llc filed Critical Abraxis Bioscience, Llc

2022-02-07 Publication of PL3313401T3 publication Critical patent/PL3313401T3/pl

Links

102000009027 Albumins Human genes 0.000 title 1
108010088751 Albumins Proteins 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
210000003237 epithelioid cell Anatomy 0.000 title 1
239000002105 nanoparticle Substances 0.000 title 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
229960002930 sirolimus Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Biomedical Technology (AREA)
Nanotechnology (AREA)
Optics & Photonics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Immunology (AREA)
Oncology (AREA)
Dermatology (AREA)
Dispersion Chemistry (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

PL16818717T 2015-06-29 2016-06-29 Nanocząsteczki zawierające sirolimus i albuminę do stosowania w leczeniu nowotworów z komórek epitelioidnych PL3313401T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562186252P	2015-06-29	2015-06-29
PCT/US2016/040170 WO2017004249A1 (en)	2015-06-29	2016-06-29	Methods of treating epithelioid cell tumors
EP16818717.7A EP3313401B1 (en)	2015-06-29	2016-06-29	Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors

Publications (1)

Publication Number	Publication Date
PL3313401T3 true PL3313401T3 (pl)	2022-02-07

Family

ID=57609139

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL21200495.6T PL3998069T3 (pl)	2015-06-29	2016-06-29	Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych
PL16818717T PL3313401T3 (pl)	2015-06-29	2016-06-29	Nanocząsteczki zawierające sirolimus i albuminę do stosowania w leczeniu nowotworów z komórek epitelioidnych

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL21200495.6T PL3998069T3 (pl)	2015-06-29	2016-06-29	Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych

Country Status (26)

Country	Link
US (3)	US10973806B2 (pl)
EP (2)	EP3998069B1 (pl)
JP (3)	JP6987644B2 (pl)
KR (2)	KR102606071B1 (pl)
CN (3)	CN108024999A (pl)
AU (2)	AU2016285720C1 (pl)
BR (1)	BR112017027954B1 (pl)
CA (1)	CA2990693C (pl)
CL (1)	CL2017003456A1 (pl)
CY (1)	CY1124926T1 (pl)
DK (1)	DK3313401T3 (pl)
EA (2)	EA202092187A1 (pl)
ES (2)	ES2897991T3 (pl)
HR (2)	HRP20211718T1 (pl)
HU (2)	HUE070408T2 (pl)
IL (1)	IL256274B2 (pl)
LT (1)	LT3313401T (pl)
MX (2)	MX381140B (pl)
PL (2)	PL3998069T3 (pl)
PT (1)	PT3313401T (pl)
RS (2)	RS66503B1 (pl)
SG (1)	SG10202107198SA (pl)
SI (1)	SI3313401T1 (pl)
SM (2)	SMT202100642T1 (pl)
WO (1)	WO2017004249A1 (pl)
ZA (1)	ZA201708567B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5933893B2 (ja)	2006-12-14	2016-06-15	アブラクシスバイオサイエンス，エルエルシー	ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法
RS59896B1 (sr)	2009-04-15	2020-03-31	Abraxis Bioscience Llc	Kompozicije nanočestica bez priona i postupci povezani sa njima
MX2012011155A (es)	2010-03-29	2012-12-05	Abraxis Bioscience Llc	Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
CA2834040C (en)	2011-04-28	2020-01-14	Abraxis Bioscience, Llc	Intravascular delivery of nanoparticle compositions and uses thereof
WO2013090634A1 (en)	2011-12-14	2013-06-20	Abraxis Bioscience, Llc	Use of polymeric excipients for lyophilization or freezing of particles
US9511046B2 (en)	2013-01-11	2016-12-06	Abraxis Bioscience, Llc	Methods of treating pancreatic cancer
US10744110B2 (en)	2013-03-12	2020-08-18	Abraxis Bioscience, Llc	Methods of treating lung cancer
KR20150127187A (ko)	2013-03-14	2015-11-16	아브락시스 바이오사이언스, 엘엘씨	방광암의 치료 방법
US10527604B1 (en)	2015-03-05	2020-01-07	Abraxis Bioscience, Llc	Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en)	2015-03-05	2020-07-07	Abraxis Bioscience, Llc	Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
HRP20211718T1 (hr)	2015-06-29	2022-03-04	Abraxis Bioscience, Llc	Nanočestice koje sadrže sirolimus i albumin za uporabu u liječenju tumora epitelioidnih stanica
MX2020009740A (es)	2018-03-20	2021-01-20	Abraxis Bioscience Llc	Metodos para el tratamiento de trastornos del sistema nervioso central mediante la administracion de nanoparticulas de un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y una albumina.
BR112020023431A2 (pt) *	2018-05-22	2021-02-23	Abraxis Bioscience, Llc	métodos e composições para tratamento de hipertensão pulmonar
CN109182519B (zh) *	2018-09-17	2019-06-14	中国人民解放军南京军区南京总医院	一种用于诊断acta2-mitf易位性血管周上皮样细胞肿瘤的探针组合及其应用
AU2020241730B2 (en) *	2019-03-19	2025-11-13	Abraxis Bioscience, Llc	Subcutaneous administration of nanoparticles comprising an mTOR inhibitor and albumin for treatment of diseases
TWI901608B (zh) *	2019-10-28	2025-10-21	美商亞伯辛生物科學有限責任公司	蛋白素及雷帕黴素(rapamycin)之醫藥組合物
WO2021096997A1 (en) *	2019-11-11	2021-05-20	Abraxis Bioscience, Llc	Biomarkers for nanoparticle compositions
MX2022005715A (es) *	2019-11-11	2022-09-19	Abraxis Bioscience Llc	Biomarcadores para composiciones de nanoparticulas.
EP4167958A1 (en) *	2020-06-19	2023-04-26	Yale University	Polymeric bile acid ester nanoparticles comprising an immunomodulator agent to induce antigen-specific tolerance

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5362478A (en)	1993-03-26	1994-11-08	Vivorx Pharmaceuticals, Inc.	Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5650156A (en)	1993-02-22	1997-07-22	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of nutriceuticals and compositions useful therefor
WO1994018954A1 (en)	1993-02-22	1994-09-01	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of biologics and compositions useful therefor
US5665383A (en)	1993-02-22	1997-09-09	Vivorx Pharmaceuticals, Inc.	Methods for the preparation of immunostimulating agents for in vivo delivery
US6096331A (en)	1993-02-22	2000-08-01	Vivorx Pharmaceuticals, Inc.	Methods and compositions useful for administration of chemotherapeutic agents
US20030068362A1 (en)	1993-02-22	2003-04-10	American Bioscience, Inc.	Methods and formulations for the delivery of pharmacologically active agents
US20070116761A1 (en)	1993-02-22	2007-05-24	Desai Neil P	Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en)	1993-02-22	1995-08-08	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5665382A (en)	1993-02-22	1997-09-09	Vivorx Pharmaceuticals, Inc.	Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5916596A (en)	1993-02-22	1999-06-29	Vivorx Pharmaceuticals, Inc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6528067B1 (en)	1993-02-22	2003-03-04	American Bioscience, Inc.	Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6753006B1 (en)	1993-02-22	2004-06-22	American Bioscience, Inc.	Paclitaxel-containing formulations
US6749868B1 (en)	1993-02-22	2004-06-15	American Bioscience, Inc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en)	1993-02-22	2003-03-25	American Bioscience, Inc.	Compositions and methods for administration of pharmacologically active compounds
US5997904A (en)	1993-02-22	1999-12-07	American Bioscience, Inc.	Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6565842B1 (en)	1995-06-07	2003-05-20	American Bioscience, Inc.	Crosslinkable polypeptide compositions
US8137684B2 (en)	1996-10-01	2012-03-20	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en)	1997-06-27	2003-10-23	Desai Neil P.	Compositions and methods for treatment of hyperplasia
NZ502500A (en)	1997-06-27	2002-03-28	Vivorx Pharmaceuticals Inc	Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en)	1997-06-27	2014-10-07	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP1171117A4 (en)	1999-04-22	2002-08-07	American Bioscience Inc	LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS
EP1178786A4 (en)	1999-05-21	2006-03-01	American Bioscience Inc	PHARMACOLOGICALLY ACTIVE PROTEIN STABILIZING AGENTS; METHODS OF MANUFACTURE AND METHODS OF USE
ITMI20001107A1 (it)	2000-05-18	2001-11-18	Acs Dobfar Spa	Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ITMI20020680A1 (it)	2002-03-29	2003-09-29	Acs Dobfar Spa	Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ITMI20020681A1 (it)	2002-03-29	2003-09-29	Acs Dobfar Spa	Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
DK1585548T3 (en)	2002-12-09	2018-09-03	Abraxis Bioscience Llc	COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
KR20140027554A (ko)	2002-12-09	2014-03-06	아브락시스 바이오사이언스, 엘엘씨	약리학적 물질의 조성물 및 그 전달방법
US8735394B2 (en)	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
CA3054535A1 (en)	2005-02-18	2006-08-24	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en)	2005-02-18	2007-07-19	Desai Neil P	Combinations and modes of administration of therapeutic agents and combination therapy
CN101291658B (zh)	2005-08-31	2014-04-16	阿布拉科斯生物科学有限公司	用于制备稳定性增加的水难溶性药物的组合物和方法
BRPI0615265A8 (pt)	2005-08-31	2018-03-06	Abraxis Bioscience Llc	composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
CA2645633A1 (en)	2006-04-05	2007-11-01	Novartis Ag	Combinations of therapeutic agents for treating cancer
US20080280987A1 (en)	2006-08-31	2008-11-13	Desai Neil P	Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
BRPI0622006A2 (pt)	2006-08-31	2011-12-20	Abraxis Bioscience Llc	usos de proteìna-veìculo e dìmero de colchicina ou tiocolchicina, forma unitária de dosagem, composição farmacêutica e kits
US20100112077A1 (en)	2006-11-06	2010-05-06	Abraxis Bioscience, Llc	Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
JP5933893B2 (ja)	2006-12-14	2016-06-15	アブラクシスバイオサイエンス，エルエルシー	ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法
AU2013204187B2 (en)	2007-03-07	2015-10-01	Abraxis Bioscience, Llc	Nanoparticle comprising rapamycin and albumin as anticancer agent
CN101730526A (zh) *	2007-03-07	2010-06-09	阿布拉科斯生物科学有限公司	作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
PT2481409T (pt)	2007-03-07	2018-10-18	Abraxis Bioscience Llc	Nanopartícula que compreende rapamicina e albumina como agente anticancerígeno
WO2008137148A2 (en)	2007-05-03	2008-11-13	Abraxis Bioscience, Llc	Methods and compositions for treating pulmonary hypertension
JP5579057B2 (ja)	2007-06-01	2014-08-27	アブラクシスバイオサイエンス，エルエルシー	再発性癌の処置のための方法および組成物
US9243052B2 (en)	2007-08-17	2016-01-26	Daniel Olive	Method for treating and diagnosing hematologic malignancies
RU2010145529A (ru)	2008-04-10	2012-05-20	АБРАКСИС БАЙОСАЙЕНС ЭлЭлСи (US)	Композиции гидрофобных производных таксана и их применение
WO2009126401A1 (en)	2008-04-10	2009-10-15	Abraxis Bioscience, Llc	Compositions of hydrophobic taxane derivatives and uses thereof
US20120128732A1 (en)	2008-12-11	2012-05-24	Vuong Trieu	Combinations and modes of administration of therapeutic agents and combination therapy
CN102281761A (zh)	2009-01-14	2011-12-14	健康研究股份有限公司	用于增强免疫应答的方法和含有mTOR抑制剂的组合物
MX2011009452A (es)	2009-03-13	2011-11-29	Abraxis Bioscience Llc	Terapia de combinacion con derivados tiocolchicina.
EP2416650B1 (en)	2009-04-10	2020-02-26	Abraxis BioScience, LLC	Nanoparticle formulations and uses therof
RS59896B1 (sr)	2009-04-15	2020-03-31	Abraxis Bioscience Llc	Kompozicije nanočestica bez priona i postupci povezani sa njima
NZ598588A (en)	2009-08-25	2014-05-30	Abraxis Bioscience Llc	Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
ES2580135T3 (es)	2010-03-26	2016-08-19	Abraxis Bioscience, Llc	Métodos de tratamiento de carcinoma hepatocelular
RU2016119999A (ru)	2010-03-29	2018-11-08	АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи	Способы лечения онкологических заболеваний
MX2012011155A (es)	2010-03-29	2012-12-05	Abraxis Bioscience Llc	Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MY188911A (en)	2010-06-02	2022-01-13	Abraxis Bioscience Llc	Methods of treating bladder cancer
KR20190130050A (ko)	2010-06-04	2019-11-20	아브락시스 바이오사이언스, 엘엘씨	췌장암의 치료 방법
SG185798A1 (en)	2010-06-07	2013-01-30	Abraxis Bioscience Llc	Combination therapy methods for treating proliferative diseases
CA2834040C (en)	2011-04-28	2020-01-14	Abraxis Bioscience, Llc	Intravascular delivery of nanoparticle compositions and uses thereof
WO2013090634A1 (en)	2011-12-14	2013-06-20	Abraxis Bioscience, Llc	Use of polymeric excipients for lyophilization or freezing of particles
HK1203971A1 (en)	2012-05-15	2015-11-06	Bristol-Myers Squibb Company	Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US9149455B2 (en)	2012-11-09	2015-10-06	Abraxis Bioscience, Llc	Methods of treating melanoma
US20140186447A1 (en)	2012-12-28	2014-07-03	Abraxis Bioscience, Llc	Nanoparticle compositions of albumin and paclitaxel
US20140199404A1 (en)	2013-01-11	2014-07-17	Abraxis Bioscience, Llc	Method for treating cancer based on level of a nucleoside transporter
US20140199405A1 (en)	2013-01-11	2014-07-17	Abraxis Bioscience, Llc	Method for treating cancer based on mutation status of k-ras
US9511046B2 (en)	2013-01-11	2016-12-06	Abraxis Bioscience, Llc	Methods of treating pancreatic cancer
MX377729B (es)	2013-02-11	2025-03-11	Abraxis Bioscience Llc	Métodos para tratamiento del melanoma.
US10744110B2 (en)	2013-03-12	2020-08-18	Abraxis Bioscience, Llc	Methods of treating lung cancer
HK1219231A1 (zh)	2013-03-13	2017-03-31	阿布拉科斯生物科学有限公司	治疗儿童实体瘤的方法
KR20150127187A (ko)	2013-03-14	2015-11-16	아브락시스 바이오사이언스, 엘엘씨	방광암의 치료 방법
CA2906678A1 (en)	2013-03-15	2014-09-18	Memorial Sloan-Kettering Cancer Center	Biomarkers for response to rapamycin analogs
EP2967059A4 (en) *	2013-03-15	2017-03-22	The Board of Regents of The University of Texas System	Use of mtor inhibitors for prevention of neuroendocrine tumor development and growth
CA2908954C (en)	2013-04-17	2021-08-03	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
WO2015157120A1 (en)	2014-04-06	2015-10-15	Abraxis Bioscience, Llc	Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
US10527604B1 (en)	2015-03-05	2020-01-07	Abraxis Bioscience, Llc	Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en)	2015-03-05	2020-07-07	Abraxis Bioscience, Llc	Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
WO2016141365A1 (en)	2015-03-05	2016-09-09	Abraxis Bioscience, Llc	Method for treating cancer based on level of glucocorticoid receptor
IL256378B2 (en)	2015-06-29	2023-03-01	Abraxis Bioscience Llc	Methods for the treatment of hematological malignancy using combined treatment with mtor inhibitor nanoparticles
HRP20211718T1 (hr)	2015-06-29	2022-03-04	Abraxis Bioscience, Llc	Nanočestice koje sadrže sirolimus i albumin za uporabu u liječenju tumora epitelioidnih stanica
KR102708679B1 (ko)	2015-06-29	2024-09-24	아브락시스 바이오사이언스, 엘엘씨	나노입자 조성물에 대한 바이오마커
EP3313382A4 (en)	2015-06-29	2019-03-06	Abraxis BioScience, LLC	METHOD FOR TREATING SOLID TUMORS WITH NANOPARTICLE-MTOR INHIBITOR COMBINATION THERAPY
US20170181988A1 (en)	2015-12-23	2017-06-29	Cipla Limited	Methods for the treatment of bladder cancer
WO2017201189A1 (en)	2016-05-17	2017-11-23	Abraxis Bioscience, Llc	Methods for assessing neoadjuvant therapies
AU2017335902B2 (en)	2016-09-28	2023-08-24	Abraxis Bioscience, Llc	Methods of treating mitochondrial and metabolic disorders
BR112019006329A2 (pt)	2016-10-07	2019-06-25	Abraxis Bioscience Llc	métodos de tratamento de câncer do trato biliar
WO2018071399A1 (en)	2016-10-10	2018-04-19	Abraxis Bioscience, Llc	Nanoparticle formulations and methods of making and using thereof
US20180374583A1 (en)	2017-05-16	2018-12-27	Abraxis Bioscience, Llc	Nomogram and survival predictions for pancreatic cancer
BR112020012060A2 (pt)	2017-12-19	2020-11-24	Abraxis Bioscience, Llc	métodos de tratamento de câncer de cólon usando uma terapia de combinação com nanopartícula de inibidor de mtor
MX2020009740A (es)	2018-03-20	2021-01-20	Abraxis Bioscience Llc	Metodos para el tratamiento de trastornos del sistema nervioso central mediante la administracion de nanoparticulas de un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y una albumina.
BR112020023431A2 (pt)	2018-05-22	2021-02-23	Abraxis Bioscience, Llc	métodos e composições para tratamento de hipertensão pulmonar
AU2020241730B2 (en)	2019-03-19	2025-11-13	Abraxis Bioscience, Llc	Subcutaneous administration of nanoparticles comprising an mTOR inhibitor and albumin for treatment of diseases
TWI901608B (zh)	2019-10-28	2025-10-21	美商亞伯辛生物科學有限責任公司	蛋白素及雷帕黴素(rapamycin)之醫藥組合物
MX2022005715A (es)	2019-11-11	2022-09-19	Abraxis Bioscience Llc	Biomarcadores para composiciones de nanoparticulas.

2016
- 2016-06-29 HR HRP20211718TT patent/HRP20211718T1/hr unknown
- 2016-06-29 RS RS20250101A patent/RS66503B1/sr unknown
- 2016-06-29 SM SM20210642T patent/SMT202100642T1/it unknown
- 2016-06-29 SI SI201631392T patent/SI3313401T1/sl unknown
- 2016-06-29 HR HRP20250141TT patent/HRP20250141T1/hr unknown
- 2016-06-29 ES ES16818717T patent/ES2897991T3/es active Active
- 2016-06-29 BR BR112017027954-1A patent/BR112017027954B1/pt active IP Right Grant
- 2016-06-29 CA CA2990693A patent/CA2990693C/en active Active
- 2016-06-29 PL PL21200495.6T patent/PL3998069T3/pl unknown
- 2016-06-29 MX MX2017016322A patent/MX381140B/es unknown
- 2016-06-29 DK DK16818717.7T patent/DK3313401T3/da active
- 2016-06-29 RS RS20211383A patent/RS62743B1/sr unknown
- 2016-06-29 CN CN201680047512.0A patent/CN108024999A/zh active Pending
- 2016-06-29 PL PL16818717T patent/PL3313401T3/pl unknown
- 2016-06-29 EA EA202092187A patent/EA202092187A1/ru unknown
- 2016-06-29 SG SG10202107198SA patent/SG10202107198SA/en unknown
- 2016-06-29 JP JP2017568129A patent/JP6987644B2/ja active Active
- 2016-06-29 SM SM20250058T patent/SMT202500058T1/it unknown
- 2016-06-29 EP EP21200495.6A patent/EP3998069B1/en active Active
- 2016-06-29 LT LTEPPCT/US2016/040170T patent/LT3313401T/lt unknown
- 2016-06-29 EA EA201890157A patent/EA036790B1/ru not_active IP Right Cessation
- 2016-06-29 AU AU2016285720A patent/AU2016285720C1/en active Active
- 2016-06-29 HU HUE21200495A patent/HUE070408T2/hu unknown
- 2016-06-29 KR KR1020187002290A patent/KR102606071B1/ko active Active
- 2016-06-29 CN CN202310468556.2A patent/CN116473964A/zh active Pending
- 2016-06-29 WO PCT/US2016/040170 patent/WO2017004249A1/en not_active Ceased
- 2016-06-29 ES ES21200495T patent/ES3009356T3/es active Active
- 2016-06-29 EP EP16818717.7A patent/EP3313401B1/en active Active
- 2016-06-29 HU HUE16818717A patent/HUE057175T2/hu unknown
- 2016-06-29 PT PT168187177T patent/PT3313401T/pt unknown
- 2016-06-29 US US15/737,936 patent/US10973806B2/en active Active
- 2016-06-29 KR KR1020237040035A patent/KR102798594B1/ko active Active
- 2016-06-29 CN CN202310469088.0A patent/CN116585310A/zh active Pending
2017
- 2017-12-12 IL IL256274A patent/IL256274B2/en unknown
- 2017-12-14 MX MX2021002455A patent/MX2021002455A/es unknown
- 2017-12-15 ZA ZA2017/08567A patent/ZA201708567B/en unknown
- 2017-12-28 CL CL2017003456A patent/CL2017003456A1/es unknown
2021
- 2021-02-02 US US17/165,652 patent/US12133844B2/en active Active
- 2021-11-05 CY CY20211100959T patent/CY1124926T1/el unknown
- 2021-12-01 JP JP2021195392A patent/JP7351888B2/ja active Active
- 2021-12-13 AU AU2021286245A patent/AU2021286245B2/en active Active
2023
- 2023-09-14 JP JP2023149163A patent/JP7738612B2/ja active Active
2024
- 2024-10-02 US US18/904,999 patent/US20250248978A1/en active Pending

Also Published As

Publication number	Publication date
EA202092187A1 (ru)	2021-08-31
EP3998069A1 (en)	2022-05-18
US12133844B2 (en)	2024-11-05
HUE057175T2 (hu)	2022-04-28
JP2023175811A (ja)	2023-12-12
AU2016285720C1 (en)	2022-02-03
CN116473964A (zh)	2023-07-25
KR20180021836A (ko)	2018-03-05
AU2016285720B2 (en)	2021-09-30
LT3313401T (lt)	2022-01-10
ES3009356T3 (en)	2025-03-26
SMT202500058T1 (it)	2025-03-12
CA2990693C (en)	2024-02-27
JP2022043090A (ja)	2022-03-15
US20210322391A1 (en)	2021-10-21
JP2018521057A (ja)	2018-08-02
IL256274B2 (en)	2023-02-01
RS66503B1 (sr)	2025-03-31
JP7738612B2 (ja)	2025-09-12
AU2021286245A1 (en)	2022-01-06
MX2021002455A (es)	2021-05-14
MX381140B (es)	2025-03-12
CN116585310A (zh)	2023-08-15
BR112017027954A2 (pt)	2018-08-28
CL2017003456A1 (es)	2018-05-11
SMT202100642T1 (it)	2022-03-21
EP3313401B1 (en)	2021-10-06
EP3998069B1 (en)	2024-12-11
SI3313401T1 (sl)	2022-04-29
JP6987644B2 (ja)	2022-01-05
BR112017027954B1 (pt)	2023-10-03
DK3313401T3 (da)	2021-11-15
NZ777582A (en)	2025-03-28
PT3313401T (pt)	2021-11-17
EP3313401A1 (en)	2018-05-02
JP7351888B2 (ja)	2023-09-27
CY1124926T1 (el)	2023-01-05
PL3998069T3 (pl)	2025-03-31
US20250248978A1 (en)	2025-08-07
AU2016285720A1 (en)	2018-02-01
CA2990693A1 (en)	2017-01-05
IL256274A (en)	2018-02-28
US20180177770A1 (en)	2018-06-28
KR20230165356A (ko)	2023-12-05
NZ738936A (en)	2023-08-25
MX2017016322A (es)	2018-05-02
AU2021286245B2 (en)	2024-01-18
HUE070408T2 (hu)	2025-06-28
EP3313401A4 (en)	2019-02-13
SG10202107198SA (en)	2021-08-30
HRP20250141T1 (hr)	2025-03-28
EA201890157A1 (ru)	2018-09-28
CN108024999A (zh)	2018-05-11
ES2897991T3 (es)	2022-03-03
IL256274B (en)	2022-10-01
EP3998069C0 (en)	2024-12-11
US10973806B2 (en)	2021-04-13
RS62743B1 (sr)	2022-01-31
KR102798594B1 (ko)	2025-04-18
HK1247094A1 (zh)	2018-09-21
HRP20211718T1 (hr)	2022-03-04
ZA201708567B (en)	2021-03-31
WO2017004249A1 (en)	2017-01-05
EA036790B1 (ru)	2020-12-22
KR102606071B1 (ko)	2023-11-27

Publication	Publication Date	Title
PL3998069T3 (pl)	2025-03-31	Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych
IL273856A (en)	2020-05-31	A preparation containing nanoparticles containing the drug Limousin and albumin for use in the treatment of bladder cancer
IL272596A (en)	2020-03-31	Pridopidine for use in the treatment of ALS
PT3240554T (pt)	2019-11-04	Blautia stercosis e wexlerae para uso no tratamento de doenças inflamatórias e autoimunes
GB2516814B (en)	2016-08-31	Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
EP2985301A4 (en)	2016-09-21	COPOLYMER AND HYDROPHILIC MATERIALS THEREFOR
GB201516504D0 (en)	2015-11-04	Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
PT3065759T (pt)	2021-05-17	Agentes imunossuppressores e sua utilização em terapia
SI2945642T1 (sl)	2024-07-31	Protein faktorja 1 za uporabo pri zdravljenju ali preprečevanju bolezni
SG11201701364YA (en)	2017-04-27	Battery bracket for use in electrically assisted moving body, battery unit, electrically assisted unit, and electrically assisted moving body
GB201507721D0 (en)	2015-06-17	Immunosuppressive agents and their use in therapy
IL262656A (en)	2018-12-31	Nanoliposomal irinotecan for use in the treatment of small cell lung cancer
GB201305940D0 (en)	2013-05-15	Methods and arrays for use in the same
IL259358A (en)	2018-07-31	Bis-pyridazine compounds and their use in treating cancer
PL3406258T3 (pl)	2022-06-13	Lek do stosowania w leczeniu dny moczanowej
GB201615844D0 (en)	2016-11-02	Agents for use in therapy
GB2510477B (en)	2017-12-13	Formulations for use in the treatment of chronic fatigue and associated conditions, etc
GB201916084D0 (en)	2019-12-18	1-acetyl-5-nitro-4-phenyl-3-pyrrolin-2-one for use in cancer treatment
GB201503053D0 (en)	2015-04-08	Apparatus for use in magnetic hyperthermia treatments
GB201617451D0 (en)	2016-11-30	Polypeptides for use in therapy
GB201511158D0 (en)	2015-08-05	Cell modification and application in therapy
GB201516723D0 (en)	2015-11-04	Polypeptides for use in therapy
GB201510764D0 (en)	2015-08-05	bis-Pyridazine compounds and their use in treating cancer
GB201411111D0 (en)	2014-08-06	bis-Pyridazine compounds and their use in treating cancer
GB201321564D0 (en)	2014-01-22	Uses and methods in treating obesity